NUVB Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Nuvation Bio Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.10 |
52 Week High | US$4.16 |
52 Week Low | US$0.95 |
Beta | 1.42 |
1 Month Change | -3.13% |
3 Month Change | 39.01% |
1 Year Change | 81.29% |
3 Year Change | -74.69% |
5 Year Change | n/a |
Change since IPO | -68.04% |
Recent News & Updates
Recent updates
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Shareholder Returns
NUVB | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0.6% | 0.02% | -0.6% |
1Y | 81.3% | 15.9% | 22.3% |
Return vs Industry: NUVB exceeded the US Pharmaceuticals industry which returned 14.8% over the past year.
Return vs Market: NUVB exceeded the US Market which returned 21.5% over the past year.
Price Volatility
NUVB volatility | |
---|---|
NUVB Average Weekly Movement | 17.6% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NUVB's share price has been volatile over the past 3 months.
Volatility Over Time: NUVB's weekly volatility has increased from 12% to 18% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 159 | David Hung | www.nuvationbio.com |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc. Fundamentals Summary
NUVB fundamental statistics | |
---|---|
Market cap | US$739.04m |
Earnings (TTM) | -US$68.87m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.1x
P/E RatioIs NUVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NUVB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$68.87m |
Earnings | -US$68.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.28 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NUVB perform over the long term?
See historical performance and comparison